Core Viewpoint - Newmark Group (NMRK) reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing an increase from $0.22 per share a year ago, indicating a positive earnings surprise of +19.23% [1] Financial Performance - The company achieved revenues of $759.11 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 10.68%, compared to $633.38 million in the same quarter last year [2] - Over the last four quarters, Newmark Group has consistently exceeded consensus EPS estimates and topped revenue estimates three times [2] Stock Performance - Newmark Group shares have increased approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 8.3% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.38 for the coming quarter and $1.45 for the current fiscal year, with revenues expected to be $746.65 million and $3.05 billion respectively [7] - The Zacks Rank for Newmark Group is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Real Estate - Operations industry, to which Newmark Group belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Analysts forecast that Equity Residential (EQR) will report quarterly earnings of $0.99 per share, reflecting a year-over-year increase of 2.1% and revenues of $769.26 million, which is a 4.8% increase compared to the previous year [1]. Group 1: Earnings and Revenue Estimates - The consensus EPS estimate for the quarter has been revised downward by 0.2% over the last 30 days, indicating a collective reconsideration by analysts [2]. - Analysts predict that revenues from rental income for same-store properties will reach $726.27 million, representing a 1.1% increase from the prior-year quarter [5]. - The estimated physical occupancy rate is projected to be 96.4%, unchanged from the year-ago value [5]. Group 2: Key Metrics and Performance - Analysts expect the total number of apartment units to be 85,027, an increase from the previous year's figure of 79,738 [5]. - Depreciation is anticipated to arrive at $251.20 million based on analysts' collective assessments [6]. - Over the past month, shares of Equity Residential have returned +0.8%, compared to the S&P 500 composite's +3.4% change, with a Zacks Rank of 2 (Buy) indicating expected outperformance in the near future [6].

Core Insights - Illinois Tool Works (ITW) reported quarterly earnings of $2.58 per share, exceeding the Zacks Consensus Estimate of $2.56 per share, and showing an increase from $2.54 per share a year ago [1][2] - The company achieved revenues of $4.05 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.08% and slightly up from $4.03 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +0.78%, and ITW has surpassed consensus EPS estimates in all four quarters over the past year [2] - The previous quarter's earnings were also above expectations, with actual earnings of $2.38 per share compared to an estimate of $2.34 per share, resulting in a surprise of +1.71% [2] Stock Performance and Outlook - ITW shares have increased by approximately 2.3% since the beginning of the year, while the S&P 500 has gained 8.3% [4] - The current consensus EPS estimate for the upcoming quarter is $2.67, with expected revenues of $4.03 billion, and for the current fiscal year, the estimate is $10.30 on revenues of $15.91 billion [8] Industry Context - The Manufacturing - General Industrial industry, to which ITW belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ITW's stock performance [6][9]

Core Insights - Wall Street analysts forecast Axon Enterprise (AXON) to report quarterly earnings of $1.54 per share, reflecting a year-over-year increase of 28.3, with revenues expected to reach $642.98 million, a 27.6% increase compared to the previous year [1] - The consensus EPS estimate has been revised upward by 12% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2] - Analysts predict 'Net Sales- Products' will reach $364.23 million, showing a year-over-year change of +23.4% [4] - 'Net Sales- Services' is projected to be $282.58 million, indicating a +35.3% change from the year-ago quarter [5] - The combined estimate for 'Annual recurring revenue' is expected to be $1,148.53 million, compared to $850.00 million from the previous year [5] - Axon shares have decreased by 6% in the past month, while the Zacks S&P 500 composite has increased by 3.4%, with a Zacks Rank 2 (Buy) suggesting expected outperformance in the near term [5]

Group 1 - LENZ Therapeutics, Inc. reported a quarterly loss of $0.53 per share, which was better than the Zacks Consensus Estimate of a loss of $0.58, representing an earnings surprise of +8.62% [1] - The company posted revenues of $5 million for the quarter ended June 2025, in line with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - LENZ Therapeutics shares have increased approximately 9.7% since the beginning of the year, outperforming the S&P 500's gain of 8.3% [3] Group 2 - The earnings outlook for LENZ Therapeutics will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The estimate revisions trend for LENZ Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.70 on revenues of $5.63 million, and -$2.72 on revenues of $8.8 million for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which LENZ Therapeutics belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

BRP Inc. (DOOO) shares soared 7.4% in the last trading session to close at $53.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.9% gain over the past four weeks. Shares of BRP are up as the company is making good progress on reducing inventory. It is also gearing up for major product launches. Sales of BRP's Manitou asset sale, part of a broader Marine divestment strategy, has also streamlined portfolio. Further boosting sen ...

Company Performance - Chefs' Warehouse reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and up from $0.40 per share a year ago, representing an earnings surprise of +15.56% [1] - The company achieved revenues of $1.03 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.47%, compared to $954.7 million in the same quarter last year [2] - Over the last four quarters, Chefs' Warehouse has consistently surpassed consensus EPS estimates and topped revenue estimates three times [2] Stock Performance - Chefs' Warehouse shares have increased approximately 24.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $972.16 million, and for the current fiscal year, it is $1.65 on revenues of $4.02 billion [7] Industry Outlook - The Zacks Industry Rank indicates that the Food - Miscellaneous sector is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [8] - The performance of Chefs' Warehouse may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Hayward Holdings, Inc. reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and showing an increase from $0.21 per share a year ago, resulting in an earnings surprise of +9.09% [1] - The company achieved revenues of $299.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.39% and increasing from $284.39 million year-over-year [2] - Hayward Holdings has consistently surpassed consensus EPS estimates over the last four quarters [2] Earnings Outlook - The future performance of Hayward Holdings' stock will largely depend on management's commentary during the earnings call and the sustainability of the stock's immediate price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $231 million, while the estimate for the current fiscal year is $0.72 on revenues of $1.08 billion [7] Industry Context - The Electronics - Miscellaneous Products industry, to which Hayward Holdings belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Vita Coco Company reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.36 per share, and up from $0.32 per share a year ago, representing an earnings surprise of +5.56% [1] - The company achieved revenues of $168.76 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.81%, compared to $144.12 million in the same quarter last year [2] - Over the last four quarters, the company has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] 分组2 - The stock has underperformed the market with a loss of about 0.4% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.33 on revenues of $155.49 million, and for the current fiscal year, it is $1.14 on revenues of $580.38 million [7] - The Beverages - Soft drinks industry is currently in the top 10% of the Zacks industries, indicating a favorable outlook for the sector [8]

Company Performance - Idex (IEX) reported quarterly earnings of $2.07 per share, exceeding the Zacks Consensus Estimate of $2 per share, and showing a slight increase from $2.06 per share a year ago, resulting in an earnings surprise of +3.50% [1] - The company achieved revenues of $865.4 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.96% and increasing from $807.2 million year-over-year [2] - Over the last four quarters, Idex has consistently surpassed consensus EPS estimates and topped revenue estimates three times [2] Future Outlook - The sustainability of Idex's stock price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.20 on revenues of $872.66 million, and for the current fiscal year, it is $8.24 on revenues of $3.45 billion [7] - The estimate revisions trend for Idex was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Manufacturing - General Industrial industry, to which Idex belongs, is currently ranked in the top 10% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]